Novartis AG is hammering home its commitment to immune-dermatology by in-licensing MOR106, a novel antibody against IL-17C indicated in atopic dermatitis (AtD), from biotechs Galapagos NV and MorphoSys AG for €95m ($111m) upfront, which the companies will split 50/50.
The Swiss pharma's key new product, Cosentyx (secukinumab) an antibody targeting IL-17A for psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
